Skip to main content
  • Patients
    • BAROSTIM THERAPY for Heart Failure
    • BAROSTIM NEO and You
    • Patient Stories

    BAROSTIM THERAPY for Heart Failure

    Are heart failure symptoms impacting your life? You are not alone. Millions of people worldwide suffer from these life-altering symptoms. BAROSTIM THERAPY is an effective solution to safely reduce symptoms of heart failure.

    Learn More

    BAROSTIM NEO and You

    BAROSTIM NEO is proven to safely reduce symptoms of heart failure.

    Learn More

    Patient Stories

    Real stories from patients that have asked if the BAROSTIM NEO is right for them.

    Learn More
  • Healthcare Professionals
    • Heart Failure Trial Results
    • About BAROSTIM NEO
    • Publications
    • Reimbursement
    • Medical Education
    • Clinical Research

    Heart Failure Trial Results

    BAROSTIM NEO addresses a significant unmet medical need in the treatment of heart failure.

    Learn More

    About BAROSTIM NEO

    BAROSTIM NEO is an implantable device that is clinically proven to safely reduce symptoms of heart failure.

    Learn More

    Publications

    CVRx is committed to the continued publication of clinical evidence supporting the benefit of BAROSTIM THERAPY for the treatment of heart failure.

    Learn More

    Reimbursement

    CVRx provides full BAROSTIM THERAPY Patient Access Program support to all providers.

    Learn More

    Medical Education

    Learn more about BAROSTIM THERAPY clinical evidence, patient selection and implant procedure from the experts.

    Learn More

    Clinical Research

    CVRx is committed to the generation of clinical evidence, including investigator-sponsored research, to support the adoption and access to our therapies.

    Learn More
  • About Us
    • Our Company
    • Our Team
    • Newsroom
    • Resources

    Our Company

    CVRx® is a leader in innovative technologies that address the unmet needs in cardiovascular diseases with safe and effective therapies.

    Learn More

    Our Team

    We are proud of our reputation for attracting some of the brightest leaders in the medical technology industry.

    Learn More

    Newsroom

    Latest press releases and company statements.

    Learn More

    Resources

    Downloads are made available to provide background information about us, our products and the conditions they treat.

    Learn More
  • Contact Us

Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Author: Jonathan McLellan

Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

Posted on April 7, 2021April 7, 2021 by Jonathan McLellan

March 26, 2021

Read the paper
Posted in Articles, Newsroom, White PapersLeave a Comment on Cost-impact analysis of baroreflex activation therapy in chronic heart failure patients in the United States

CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing

Posted on January 5, 2021January 6, 2021 by Jonathan McLellan

Effective January 5, 2021

Read Press Release
Posted in Newsroom, PublicationsLeave a Comment on CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing

CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status

Posted on December 3, 2020December 3, 2020 by Jonathan McLellan

Effective December 2, 2020

Read Press Release
Posted in Articles, NewsroomLeave a Comment on CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts

Posted on November 18, 2020January 6, 2021 by Jonathan McLellan

Effective November 18, 2020

Read Press Release
Posted in Articles, Newsroom, PublicationsLeave a Comment on CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts

CVRx’s BAROSTIM NEO™ Receives CMS NTAP

Posted on October 1, 2020November 12, 2020 by Jonathan McLellan

Effective October 1, 2020

READ PRESS RELEASE
Posted in Newsroom, PublicationsTagged Barostim, CMS NTAP, Heart FailureLeave a Comment on CVRx’s BAROSTIM NEO™ Receives CMS NTAP

Neuromodulation for Heart Failure, a New Therapeutic Frontier

Posted on August 30, 2020September 2, 2020 by Jonathan McLellan
Posted in Newsroom, PublicationsLeave a Comment on Neuromodulation for Heart Failure, a New Therapeutic Frontier

Ready to learn more about Barostim?

Large Photo
Patients
  • BAROSTIM THERAPY for Heart Failure
  • BAROSTIM NEO and You
  • Patient Stories
Healthcare Profesionals
  • Heart Failure Trial Results
  • About BAROSTIM NEO
  • Publications
  • Reimbursement
About Us
  • Overview
  • Our Team
  • Newsroom
  • Downloadable Images
  • Contact Us
Connect

©2021 CVRx. All Rights Reserved.

  • Intellectual Property
  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • AdvaMed Code of Ethics
  • MedTech Europe Code of Ethics
  • Important Safety & Regulatory Information
Ready to get started with Barostim?